Maximizing Employee Stock Options: Insider Strategiesby Mark Eisenberg 12.02.2024Learn how to maximize the value of your employee stock options (ESOs) with strategies, tips, and long-term planning. A comprehensive ...
Grand Canyon Education: Earnings Anticipation High.by Mark Eisenberg 12.02.2024Grand Canyon Education set to release Q4 earnings report, with analysts predicting 6.4% revenue growth. Positive sentiment in consumer discretionary ...
MGM Resorts Earnings: Strong Revenue Growth Expectedby Mark Eisenberg 12.02.2024MGM Resorts is expected to announce strong Q4 earnings with a 15.1% YoY increase in revenue. Analysts are optimistic about ...
Hasbro Earnings: Revenue Decline Aheadby Mark Eisenberg 12.02.2024Toy and entertainment company Hasbro is expected to face a challenging quarter with a decline in revenue and adjusted earnings. ...
Denny’s Q4 Earnings: Analysts Predict Revenue Declineby Mark Eisenberg 12.02.2024Denny's is expected to report a decline in Q4 revenue, raising concerns among investors. Analysts have revised estimates downward, but ...
Is the Momentum Trade Bubble About to Burst? – Analyst Jonathan Krinsky Discusses Market Inflectionby Mark Eisenberg 12.02.2024The winning momentum trade may be losing steam, according to technical analyst Jonathan Krinsky. The market could experience a turning ...
Evercore Stands By FIS Amid Market Pressuresby Mark Eisenberg 12.02.2024Evercore ISI maintains "In Line" rating on Fidelity National Information Services (FIS) despite challenges in its Banking Solutions and Capital ...
S&P 500 Hits Historic 5000: What’s Next?by Mark Eisenberg 12.02.2024The S&P 500 has reached a historic milestone, surpassing 5000 points for the first time and doubling since the pandemic ...
Academy Sports & Outdoors: Guggenheim Raises Targetby Mark Eisenberg 12.02.2024Guggenheim reaffirms Buy rating on Academy Sports & Outdoors (NASDAQ:ASO) with a price target of $75. The stock has surged ...
Atossa Genetics: Potential Breakthrough in Breast Cancer?by Lilu Anderson 12.02.2024Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...